what happens around us is here

HIV/AIDS Update – Tentaive approval of generic nevirapine tablets, 200 mg

On March 31, 2009, the Food and Drug Administration granted tentative approval for a generic formulation of nevirapine tablets, USP, 200 mg indicated for combination antiretroviral treatment of HIV-1 infection. Manufactured by MacLeods Pharmaceuticals Limited of Daman, India, this tentatively approved formulation is a generic version of the Nonnucleoside Reverse Transcriptase Inhibitor, (NNRTI), Viramune tablets, USP, 200 mg, manufactured by Boehringer Ingelheim.

“Tentative approval” means that FDA has concluded that a drug product meets all required quality, safety and efficacy standards, but is not presently eligible for final approval or marketing in the U.S. because of existing patents and/or exclusivity rights. However, tentative approval does make the product eligible for purchase outside the United States under the President’s Emergency Plan for AIDS Relief (PEPFAR).

Effective patent dates can be found in the agency’s publication titled Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.

The application was reviewed under expedited review provisions for PEPFAR.

Richard Klein
of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration


April 5, 2009 - Posted by | 1

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: